(NASDAQ: BRTX) Biorestorative Therapies's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.48%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.1%.
Biorestorative Therapies's earnings in 2026 is -$14,241,975.On average, 4 Wall Street analysts forecast BRTX's earnings for 2026 to be -$19,490,800, with the lowest BRTX earnings forecast at -$29,213,270, and the highest BRTX earnings forecast at -$8,828,186. On average, 4 Wall Street analysts forecast BRTX's earnings for 2027 to be -$10,525,032, with the lowest BRTX earnings forecast at -$12,983,675, and the highest BRTX earnings forecast at -$7,758,103.
In 2028, BRTX is forecast to generate -$10,654,971 in earnings, with the lowest earnings forecast at -$12,234,617 and the highest earnings forecast at -$8,828,186.